Market openNon-fractional
CureVac/CVAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About CureVac
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Ticker
CVAC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
TĂĽbingen, Germany
Employees
1,086
Website
www.curevac.com
CureVac Metrics
BasicAdvanced
$758M
Market cap
-
P/E ratio
-$1.32
EPS
2.67
Beta
-
Dividend rate
Price and volume
Market cap
$758M
Beta
2.67
Financial strength
Current ratio
2.25
Quick ratio
2.014
Long term debt to equity
7.955
Total debt to equity
9.094
Management effectiveness
Return on assets (TTM)
-21.53%
Return on equity (TTM)
-47.11%
Valuation
Price to revenue (TTM)
10.943
Price to book
1.57
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
-2.07
Growth
Revenue change (TTM)
17.59%
Earnings per share change (TTM)
-18.28%
3-year revenue growth
1.89%
3-year earnings per share growth
-0.27%
What the Analysts think about CureVac
Analyst Ratings
Majority rating from 9 analysts.
CureVac Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€12M
-45.33%
Net income
-€71M
-18.59%
Profit margin
-573.17%
48.92%
CureVac Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€0.30
-€0.22
-€0.39
-€0.31
-
Expected
-€0.24
-€0.23
-€0.19
-€0.23
-€0.24
Surprise
25.00%
-3.51%
110.81%
35.96%
-
CureVac News
AllArticlesVideos
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
Barrons·2 days ago
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
Market Watch·2 days ago
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $758M as of July 05, 2024.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 0 as of July 05, 2024.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell CureVac stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.